Controlled drug delivery systems in eradicating bacterial biofilm-associated infections

Liu, Yong; Li, Yuanfeng; Shi, Linqi

doi:10.1016/j.jconrel.2020.10.038

Cited by 59 publications

(40 citation statements)

References 159 publications

(219 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the clinical use of colistin was discontinued and replaced with other effective antibiotics. However, the increasing challenges caused by multi-drug resistant Gram-negative bacteria, together with the lack of new type antibiotics against such strains have made colistin come back into the spotlight ( Liu et al, 2021 ; Su et al, 2021 ). Worse still, many clinically isolated pathogens are resistant to colistin treatment.…”

Section: Discussionmentioning

confidence: 99%

Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin

et al. 2021

View full text Add to dashboard Cite

Colistin is being considered as “the last ditch” treatment in many infections caused by Gram-negative stains. However, colistin is becoming increasingly invalid in treating patients who are infected with colistin-resistant Escherichia coli (E. coli) and Klebsiella Pneumoniae (K. pneumoniae). To cope with the continuous emergence of colistin resistance, the development of new drugs and therapies is highly imminent. Herein, in this work, we surprisingly found that the combination of quercetin with colistin could efficiently and synergistically eradicate the colistin-resistant E. coli and K. pneumoniae, as confirmed by the synergy checkboard and time-kill assay. Mechanismly, the treatment of quercetin combined with colistin could significantly downregulate the expression of mcr-1 and mgrB that are responsible for colistin-resistance, synergistically enhancing the bacterial cell membrane damage efficacy of colistin. The colistin/quercetin combination was notably efficient in eradicating the colistin-resistant E. coli and K. pneumoniae both in vitro and in vivo. Therefore, our results may provide an efficient alternative pathway against colistin-resistant E. coli and K. pneumoniae infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The avidin–biotin complex (ABC) method of cell-drug interaction involves the use of biotin which binds to the MSC surface and will then rapidly and stably form a covalent bond with an avidin-coated particle (reviewed in [ 15 ]). Alternatively, the MSC can be ‘avidinated’ followed by binding of biotinylated drug molecules [ 16 ] and liposomes [ 17 ] (Table 1 ).…”

Section: Mscs As Drug Delivery Vectorsmentioning

confidence: 99%

Enhancement strategies for mesenchymal stem cells and related therapies

et al. 2022

View full text Add to dashboard Cite

Cell therapy, particularly mesenchymal stem/stromal (MSC) therapy, has been investigated for a wide variety of disease indications, particularly those with inflammatory pathologies. However, recently it has become evident that the MSC is far from a panacea. In this review we will look at current and future strategies that might overcome limitations in efficacy. Many of these take their inspiration from stem cell niche and the mechanism of MSC action in response to the injury microenvironment, or from previous gene therapy work which can now benefit from the added longevity and targeting ability of a live cell vector. We will also explore the nascent field of extracellular vesicle therapy and how we are already seeing enhancement protocols for this exciting new drug. These enhanced MSCs will lead the way in more difficult to treat diseases and restore potency where donors or manufacturing practicalities lead to diminished MSC effect.

show abstract

“…Binding of a drug to its carrier is often accompanied by an alteration of its distribution, which is beneficial when its increased accumulation in the target tissue is desirable. Biodistribution of a bound drug depends on the properties of the carrier [ 73 , 74 , 75 ].…”

Section: Conjugates For Drug Deliverymentioning

confidence: 99%

Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components

et al. 2021

View full text Add to dashboard Cite

Regenerative medicine is becoming a rapidly evolving technique in today’s biomedical progress scenario. Scientists around the world suggest the use of naturally synthesized biomaterials to repair and heal damaged cells. Hydroxyapatite (HAp) has the potential to replace drugs in biomedical engineering and regenerative drugs. HAp is easily biodegradable, biocompatible, and correlated with macromolecules, which facilitates their incorporation into inorganic materials. This review article provides extensive knowledge on HAp and collagen-containing compositions modified with drugs, bioactive components, metals, and selected nanoparticles. Such compositions consisting of HAp and collagen modified with various additives are used in a variety of biomedical applications such as bone tissue engineering, vascular transplantation, cartilage, and other implantable biomedical devices.

show abstract

Controlled drug delivery systems in eradicating bacterial biofilm-associated infections

Abstract: Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cited by 59 publications

References 159 publications

Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin

Quercetin Rejuvenates Sensitization of Colistin-Resistant Escherichia coli and Klebsiella Pneumoniae Clinical Isolates to Colistin

Enhancement strategies for mesenchymal stem cells and related therapies

Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components

Contact Info

Product

Resources

About